Endoscopic Treatment for Early Foregut Neuroendocrine Tumors

Moo In Park
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

Foregut neuroendocrine tumors (NETs) include those arising in the esophagus, stomach, pancreas, and duodenum and seem to have a broad range of clinical behavior from benign to metastatic. Several factors including the advent of screening endoscopy may be related to increased incidence of gastrointestinal NETs; thus, many foregut NETs are diagnosed at an early stage. Early foregut NETs, such as those of the stomach and duodenum, can be managed with endoscopic treatment because of a low frequency of lymph node and distant metastases. However, controversy continues concerning the optimal management of early foregut NETs due to a lack of controlled prospective studies. Several issues such as indications, technical issues, and outcomes of endoscopic treatment for early foregut NETs are reviewed based on some published studies.

Key Words: Stomach; Duodenum; Neuroendocrine tumors; Endoscopic treatment

INTRODUCTION

Neuroendocrine tumors (NETs) are defined as epithelial neoplasms with predominant neuroendocrine differentiation, arising throughout the body. Gastrointestinal NETs can be classified into foregut, midgut, or hindgut depending on the point of origin in the disseminated endocrine system.1 Foregut NETs include those arising in the esophagus, stomach, pancreas, and duodenum. The new histologic grading system of 2010 World Health Organization classification for digestive system NETs that could be applied to all stages of neuroendocrine neoplasms (NENs) separates well-differentiated tumors into low grade (G1) and intermediate grade (G2) categories. All poorly differentiated NETs are high grade (G3) neuroendocrine carcinomas according to this classification scheme (Table 1).2-4

Foregut NETs seem to have a broad range of clinical behavior from benign to metastatic. The treatment of choice for a localized NET is usually surgery. Many foregut NETs are diagnosed at an early stage because of the advent of screening endoscopy and, thus, can be managed with endoscopic treatment because of a low frequency of lymph node and distant metastases. However, controversy continues concerning the optimal management of early foregut NETs due to a lack of controlled prospective studies. These debatable issues on endoscopic treatment for early foregut NETs are discussed based on some published data.

EPIDEMIOLOGY OF FOREGUT NETs

The incidence of NETs is reported to be rising in Western countries and Asia.5-8 In the United States, a significant increase in reported annual age-adjusted incidence of NETs from 1973 (1.09/100,000) to 2004 (5.25/100,000) was reported.5 Also, the incidence of NETs in Taiwan increased steadily from 1996 (0.30/100,000) to 2008 (1.51/100,000).6 Despite such increase, the incidence rate of NETs in Taiwan is lower than that of Norway and the United States.5,7 Many factors may contribute to increase the incidence of NETs around the world. These factors can be a better awareness, improved diagnostic strategies, and increased and more widespread use of gastrointestinal endoscopy.7-14 The distribution of gastrointestinal NETs seemed to be different between Japan and Western countries.4 The distribution of gastrointestinal NETs in the United States is reported to be 19.4% in the foregut, 38.7% in the midgut, and 41.9% in the hindgut.3 In contrast, in Japa-
nese population, 30.4% were in the foregut, 9.6% in the mid-gut, and 60.0% in the hindgut.³

**NEFs OF THE ESOPHAGUS**

Esophageal NEFs are extremely rare. Most cases of esophageal NEFs are poorly differentiated endocrine carcinoma (PD-EC) and mixed adenoneuroendocrine carcinoma. The few reported cases have been mostly treated by esophagogastrectomy.³

**NEFs OF THE STOMACH**

The stomach is the most common foregut location for NEFs. Gastric NEFs comprise 7% of all gastrointestinal NEFs and 2% of all removed gastric polyps.¹⁵,¹⁶ Four types of gastric NEFs have been proposed and recognition of the type is important for defining the diagnostic approach and treatment. Gastric NEFs are subdivided into four categories, with differing biologic behaviors and prognoses: type 1, arising on atrophic body gastritis; type 2, a manifestation of type 1 multiple endocrine neoplasia (MEN-I); type 3, with no specific background disease; type 4, poorly differentiated NEFs (Table 2).¹⁷

Type 1 gastric NET is the most common type and tends to be nearly all benign lesions, with a low risk for progression or metastasis. The type 1 is mostly diagnosed at an early stage, with 80% to 90% of them being ≤1 cm in diameter.¹²

**Diagnosis of early NETs of the stomach**

Endoscopy is the only method to detect early gastric NEFs that are usually asymptomatic. Widespread use of gastrointestinal endoscopy and endoscopic screening may lead to increased detection of small sized gastric NEFs.¹³ Well-differentiated NEFs are observed more often, with a 10-fold increase in the United States of the stomach (gastric carcinoid tumors) are increased detection of small sized gastric NETs.¹² Endoscopic ultrasound is very useful for determining exact tumor size and depth of invasion. However, endoscopic ultrasound is not essential for type 1 gastric NETs measuring less than 1 cm, because those generally do not infiltrate the muscular layer.¹⁷ Abdominal ultrasound and computed tomography are usually performed if malignancy is suspected.¹³,¹⁷

**Table 1. World Health Organization 2010 Classification and Suggested Grading of Neuroendocrine Neoplasms of the Digestive System**

| Classification | Grade | Mitotic count (per 10 HPF) | Ki-67 index, % |
|---------------|-------|---------------------------|----------------|
| NET           | G1⁺⁺  | <2                        | ≤2             |
| NET           | G2⁺   | 2-20                      | 3-20           |
| NEC           | G3⁺⁺  | >20                       | >20            |

Adapted from Rindi et al. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer; 2010. p. 13. with the permission of the publisher.³ HPF, high power field; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma.

⁴G1, low-grade tumors; ⁵G2, intermediate-grade tumors; ⁶G3, high-grade tumors.

**Therapy of Gastric Neuroendocrine Neoplasms**

- **Type 1**
  - Surveillance{⁷}
  - EMR followed by surveillance
- **Type 2**
  - Surveillance{⁸}
  - EMR followed by surveillance
- **Type 3**
  - EMR
  - Surgery
- **Type 4**
  - Surgery

Adapted from Scherübl et al. World J Gastrointest Endosc 2011;3:133-139.⁷

EMR, endoscopic mucosal resection.

²Risk factors for metastatic disease are angioinvasion or G2-G3 histological grading or infiltration of the muscularis propria or tumor size > 2 cm; ³Somatostatin analogs are being tested in ongoing clinical trials, they should not be used except in clinical trials; ⁴Followed by endoscopic surveillance of the gastric remnant. Adjuvant (medical) therapy is not established in NET/carcinoid disease; ⁵Surgery in localized type 4 gastric/d neuroendocrine carcinoma (NEC) disease (or systemic cytoreductive chemotherapy in advanced type 4 gastric NEC disease). Type 4 gastric NECs are never benign, they are neuroendocrine carcinomas.
Endoscopic Treatment for Early For gut NETs

Endoscopic surveillance at 12 mo

Recurrence

Endoscopic resection

Type 2 (GC-2)
ZES
MEN 1

Type 1 (GC-1)
Hypo/achlorhydria
Chronic atrophic gastritis

Histology with chromogranin A

Hypo/achlorhydria

Sporadic

Type 3 (GC-3)

Normal gastrin
CgA

< 1 cm
≥ 1 cm
< 6 polyps
Not involving muscularis propria
> 6 lesions
Involving muscularis propria

Surgery
chemotherapy

Fig. 1. Management of gastric carcinoids according to European Neuroendocrine Tumor Society (ENETS) guidelines. Adapted from Nikou et al. Gastroenterol Res Pract 2012;2012:287825.

Registry from Japan showed that even in minute (≤ 5 mm in diameter) and small (5.1 to 10 mm in diameter) gastric NETs at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids), metastases rate were 4.6% and 9.6%, respectively. These metastatic rates are compatible with those of gastric sm adenocarcinoma. This result suggest that when treating patients with early gastric NETs, possibility of metastases should be considered. However, the 5-year survival rates of patients with gastric sm carcinoids after endoscopic resection was 89.6%.

In the European Neuroendocrine Tumor Society Consensus Guidelines for managements of gastroenteropancreatic NETs (including carcinoid) management of type 3 gastric carcinoids is fairly clear and includes partial or total gastrectomy with extended lymph node dissection. Management of type 1 and type 2 gastric carcinoids is more controversial. In patients with type 1 gastric carcinoids less than 10 mm in diameter, annual surveillance is appropriate. Endoscopic resection is recommended in cases of tumors > 10 mm in diameter and in the presence of up to six polyps not involving the muscularis propria at EUS examination (Fig. 1).

The management of G1 NETs sized 1 to 2 cm is a matter of debate. There are no controlled studies that compared endoscopic treatment with surgical approach. In case of type 1 or 2 gastric NETs of the stomach.17 Small, less than 1 cm in diameter, well-differentiated (G1) NETs of the stomach that do not infiltrate the muscularis propria and do not show angioinvasion have a very low risk of metastatic spread. Thus, early, G1-differentiated NETs of the stomach should be removed by endoscopic methods. However, a large retrospective study using Niigata Registry from Japan showed that even in minute (≤ 5 mm in diameter) and small (5.1 to 10 mm in diameter) gastric NETs at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids), metastases rate were 4.6% and 9.6%, respectively. These metastatic rates are compatible with those of gastric sm adenocarcinoma. This result suggest that when treating patients with early gastric NETs, possibility of metastases should be considered. However, the 5-year survival rates of patients with gastric sm carcinoids after endoscopic resection was 89.6%.

In the European Neuroendocrine Tumor Society Consensus Guidelines for managements of gastroenteropancreatic NETs (including carcinoid) management of type 3 gastric carcinoids is fairly clear and includes partial or total gastrectomy with extended lymph node dissection. Management of type 1 and type 2 gastric carcinoids is more controversial. In patients with type 1 gastric carcinoids less than 10 mm in diameter, annual surveillance is appropriate. Endoscopic resection is recommended in cases of tumors > 10 mm in diameter and in the presence of up to six polyps not involving the muscularis propria at EUS examination (Fig. 1).

The management of G1 NETs sized 1 to 2 cm is a matter of debate. There are no controlled studies that compared endoscopic treatment with surgical approach. In case of type 1 or 2 gastric NETs of the stomach.17 Small, less than 1 cm in diameter, well-differentiated (G1) NETs of the stomach that do not infiltrate the muscularis propria and do not show angioinvasion have a very low risk of metastatic spread. Thus, early, G1-differentiated NETs of the stomach should be removed by endoscopic methods. However, a large retrospective study using Niigata

Registry from Japan showed that even in minute (≤ 5 mm in diameter) and small (5.1 to 10 mm in diameter) gastric NETs at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids), metastases rate were 4.6% and 9.6%, respectively. These metastatic rates are compatible with those of gastric sm adenocarcinoma. This result suggest that when treating patients with early gastric NETs, possibility of metastases should be considered. However, the 5-year survival rates of patients with gastric sm carcinoids after endoscopic resection was 89.6%.

In the European Neuroendocrine Tumor Society Consensus Guidelines for managements of gastroenteropancreatic NETs (including carcinoid) management of type 3 gastric carcinoids is fairly clear and includes partial or total gastrectomy with extended lymph node dissection. Management of type 1 and type 2 gastric carcinoids is more controversial. In patients with type 1 gastric carcinoids less than 10 mm in diameter, annual surveillance is appropriate. Endoscopic resection is recommended in cases of tumors > 10 mm in diameter and in the presence of up to six polyps not involving the muscularis propria at EUS examination (Fig. 1).

The management of G1 NETs sized 1 to 2 cm is a matter of debate. There are no controlled studies that compared endoscopic treatment with surgical approach. In case of type 1 or 2 gastric NETs of the stomach.17 Small, less than 1 cm in diameter, well-differentiated (G1) NETs of the stomach that do not infiltrate the muscularis propria and do not show angioinvasion have a very low risk of metastatic spread. Thus, early, G1-differentiated NETs of the stomach should be removed by endoscopic methods. However, a large retrospective study using Niigata

Registry from Japan showed that even in minute (≤ 5 mm in diameter) and small (5.1 to 10 mm in diameter) gastric NETs at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids), metastases rate were 4.6% and 9.6%, respectively. These metastatic rates are compatible with those of gastric sm adenocarcinoma. This result suggest that when treating patients with early gastric NETs, possibility of metastases should be considered. However, the 5-year survival rates of patients with gastric sm carcinoids after endoscopic resection was 89.6%.

In the European Neuroendocrine Tumor Society Consensus Guidelines for managements of gastroenteropancreatic NETs (including carcinoid) management of type 3 gastric carcinoids is fairly clear and includes partial or total gastrectomy with extended lymph node dissection. Management of type 1 and type 2 gastric carcinoids is more controversial. In patients with type 1 gastric carcinoids less than 10 mm in diameter, annual surveillance is appropriate. Endoscopic resection is recommended in cases of tumors > 10 mm in diameter and in the presence of up to six polyps not involving the muscularis propria at EUS examination (Fig. 1).

The management of G1 NETs sized 1 to 2 cm is a matter of debate. There are no controlled studies that compared endoscopic treatment with surgical approach. In case of type 1 or 2 gastric NETs of the stomach.17 Small, less than 1 cm in diameter, well-differentiated (G1) NETs of the stomach that do not infiltrate the muscularis propria and do not show angioinvasion have a very low risk of metastatic spread. Thus, early, G1-differentiated NETs of the stomach should be removed by endoscopic methods. However, a large retrospective study using Niigata

Registry from Japan showed that even in minute (≤ 5 mm in diameter) and small (5.1 to 10 mm in diameter) gastric NETs at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids), metastases rate were 4.6% and 9.6%, respectively. These metastatic rates are compatible with those of gastric sm adenocarcinoma. This result suggest that when treating patients with early gastric NETs, possibility of metastases should be considered. However, the 5-year survival rates of patients with gastric sm carcinoids after endoscopic resection was 89.6%.

In the European Neuroendocrine Tumor Society Consensus Guidelines for managements of gastroenteropancreatic NETs (including carcinoid) management of type 3 gastric carcinoids is fairly clear and includes partial or total gastrectomy with extended lymph node dissection. Management of type 1 and type 2 gastric carcinoids is more controversial. In patients with type 1 gastric carcinoids less than 10 mm in diameter, annual surveillance is appropriate. Endoscopic resection is recommended in cases of tumors > 10 mm in diameter and in the presence of up to six polyps not involving the muscularis propria at EUS examination (Fig. 1).

The management of G1 NETs sized 1 to 2 cm is a matter of debate. There are no controlled studies that compared endoscopic treatment with surgical approach. In case of type 1 or 2 gastric NETs of the stomach.17 Small, less than 1 cm in diameter, well-differentiated (G1) NETs of the stomach that do not infiltrate the muscularis propria and do not show angioinvasion have a very low risk of metastatic spread. Thus, early, G1-differentiated NETs of the stomach should be removed by endoscopic methods. However, a large retrospective study using Niigata

Registry from Japan showed that even in minute (≤ 5 mm in diameter) and small (5.1 to 10 mm in diameter) gastric NETs at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids), metastases rate were 4.6% and 9.6%, respectively. These metastatic rates are compatible with those of gastric sm adenocarcinoma. This result suggest that when treating patients with early gastric NETs, possibility of metastases should be considered. However, the 5-year survival rates of patients with gastric sm carcinoids after endoscopic resection was 89.6%.

In the European Neuroendocrine Tumor Society Consensus Guidelines for managements of gastroenteropancreatic NETs (including carcinoid) management of type 3 gastric carcinoids is fairly clear and includes partial or total gastrectomy with extended lymph node dissection. Management of type 1 and type 2 gastric carcinoids is more controversial. In patients with type 1 gastric carcinoids less than 10 mm in diameter, annual surveillance is appropriate. Endoscopic resection is recommended in cases of tumors > 10 mm in diameter and in the presence of up to six polyps not involving the muscularis propria at EUS examination (Fig. 1).

The management of G1 NETs sized 1 to 2 cm is a matter of debate. There are no controlled studies that compared endoscopic treatment with surgical approach. In case of type 1 or 2 gastric NETs of the stomach.17 Small, less than 1 cm in diameter, well-differentiated (G1) NETs of the stomach that do not infiltrate the muscularis propria and do not show angioinvasion have a very low risk of metastatic spread. Thus, early, G1-differentiated NETs of the stomach should be removed by endoscopic methods. However, a large retrospective study using Niigata
gastric NETs of 1 to 2 cm in diameter, the endoscopic treatment should be preferred to surgery in patients with significant comorbidities and in elderly patients with a high surgical risk (Table 3).\(^\text{17}\)

Another issue we should consider is a method of endoscopic treatments. Endoscopic submucosal dissection technique can increase complete resection rate compare with other techniques, such as endoscopic polypectomy, strip biopsy, aspiration resection, and band snare resection.\(^\text{32,35-41}\)

Rescue surgery after endoscopic resection should be considered in certain properties of foregut NETs. The indication for additional surgery is usually based on the location, type, grade, and stage of the foregut NETs. In the case of type 1 or type 2 gastric NETs with positive margins, size >20 mm, G2-G3 histologic grading, invasion into the muscularis propria or vessel infiltration of tumor cells, additional surgery is recommended.\(^\text{12}\) In the case of type 3 gastric NETs with a size >10 mm, irrespective of other risk factors, and localized type 4, rescue surgery is necessary.\(^\text{12}\)

### NENs OF THE DUODENUM

Primary duodenal NETs account for less than 2% of all gastrointestinal NETs.\(^\text{42}\) Five major types of NETs can be seen in the duodenum: 1) gastrinomas (type I) are most common and are usually seen in the proximal duodenum. One third is associated with ZES and MEN1; 2) second in frequency are somatostatinomas (type II), which often have a periampullary location. They may be associated with von Recklinghausen disease; 3) gangliocytic paragangliomas (type III) are benign tumors found at the ampulla or in the periamputillary region; 4) type IV is rare and contains tumors that produce serotonin and calcitonin; and 5) PDECs (type V) is extremely rare and highly malignant and is usually located at the ampulla of Vater.\(^\text{43}\)

#### Diagnosis of early NETs of the duodenum

Most duodenal NETs are asymptomatic and generally diagnosed during upper gastrointestinal endoscopy for unrelated symptoms. In addition, duodenal NETs are usually hormonally silent. Upper gastrointestinal endoscopy is the only method of choice to detect early duodenal NETs.\(^\text{17}\)

In a retrospective analysis of duodenal carcinoid tumors, Burke et al.\(^\text{44}\) identified three pathologic features of the primary tumor as independent risk factors for metastasis: invasion of the muscularis propria, tumor size greater than 2 cm, and the presence of mitotic figures. A retrospective study from Mayo Clinic showed that 18 of 19 patients with tumors smaller than 2 cm remained disease free after local (endoscopic or transduodenal) excision.\(^\text{38}\)

Early duodenal NETs can be considered if tumors are ≤10 mm in size, G1, show neither angioinvasion nor infiltration of the muscular layer, have no associated hormonal secretion and have a very low metastatic potential.\(^\text{17}\)

#### Treatment of early NETs of the duodenum

No consensus guidelines exist for the endoscopic management of duodenal NETs. Multiple factors must be taken into account when considering treatment options. Well-differentiated, nonfunctioning duodenal NETs with no evidence of invasion to the muscularis layer and 1 cm or less in size can be

| Table 3. Clinicopathological Characteristics of Gastric Neuroendocrine Neoplasms |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| **Gastric NETs/carcinoids**      | **Gastric NECs**                 |
| **Type 1**                       | **Type 2**                       | **Type 3**                       | **Type 4**                       |
| Relative frequency               | 70%-80%                          | 5%-6%                            | 14%-25%                          | 6%-8%                            |
| Features                         | Mostly small (<1-2 cm)           | Mostly small (<1-2 cm)           | Solitary often >2 cm             | Solitary mostly exulcerated, >2 cm|
| and multiple                     | and multiple                     |                                 |                                 |                                 |
| Associated conditions            | CAG                              | MEN1/ZES\(^\text{(a)}\)           | No                              | No                              |
| Histology                        | Well differentiated G1\(^\text{(b)}\) | Well differentiated G1\(^\text{(b)}\) | Well/moderate differentiated G2  | Poorly differentiated G3\(^\text{(c)}\) |
| Serum gastrin                    | (Very) high                      | (Very) high                      | Normal                          | (Mostly) normal                 |
| Gastric pH                       | Anacidic                         | Hyperacidic                      | Normal                          | (Mostly) normal                 |
| Metastases                       | <10%                             | 10%-30%                          | 50%-100%                        | 80%-100%                        |
| Tumor-related death              | No                               | <10%                             | 25%-30%                         | ≥50%                            |

G1-3, histological differentiation. Adapted from Modlin et al. Am J Gastroenterol 2004;99:23-32, with permission from Nature Publishing Group.\(^\text{15}\)

NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; NEN, neuroendocrine neoplasm; CAG, chronic atrophic gastritis, due to pernicious anemia or *Helicobacter pylori* infection; MEN1, multiple endocrine neoplasia type 1; ZES, Zollinger-Ellison syndrome.\(^\text{a}\)MEN1/ZES; ZES associated with MEN1;\(^\text{b}\)G1, well differentiated;\(^\text{c}\)G3, poorly differentiated.
Adjuvant (medical) therapy is not established in NET/carcinoid disease. Sporadic gastrinoma (without distant metastases). In (very) elderly patients conservative management may, however, be preferred to surgery.

For eligible foregut NETs. However, the appropriate selection criteria of foregut NETs for endoscopic resection is still controversial and further studies are needed.

Table 4. Therapy of Duodenal Neuroendocrine Neoplasms

| Type                          | ≤1 cm³ | 1-2 cm³ | Any size but risk factors³ |
|-------------------------------|--------|---------|---------------------------|
| Sporadic NET (no gastrinoma, no MEN1) | EMR    | Surgery | Surgery                   |
| Sporadic gastrinoma           | Surgery⁴| Surgery⁵| Surgery⁵                 |
| Gastrinoma and MEN1           | PPI therapy and surveillance (or surgery) | Surgery (particularly if the gastrinoma is growing) or PPI therapy combined with surveillance | Surgery (for PPI therapy combined with surveillance in GI gastrinomas and/or surgical risks) |
| NEC (G3)                      | -      | -       | Surgery or cytoreductive chemotherapy |

Adapted from Scherübl et al. World J Gastrointest Endosc 2011;3:133-139.²⁷ NET, well differentiated neuroendocrine tumor; MEN1, multiple endocrine neoplasia type 1; EMR, endoscopic mucosal resection; PPI, proton pump inhibitor; GI, gastrointestinal.

Without risk factors (for metastatic disease) such as G2-G3, angioinvasion, infiltration of the muscularis propria or tumor size >2 cm; ⁶ In the presence of risk factors for metastatic disease, surgery is generally indicated, regardless of tumor size; ⁶ Surgery is the therapy of choice for sporadic gastrinoma (without distant metastases). In (very) elderly patients conservative management may, however, be preferred to surgery. Adjuvant (medical) therapy is not established in NET/carcinoid disease.

These tumors carry a low risk for lymphatic or distant metastasis. In case of duodenal carcinoids more than 1 cm in size, the option of management is a matter of debate. A recent case series from Japan showed complete and safe results of endoscopic resection for duodenal bulb NETs more than 10 mm in size.⁴³

CONCLUSIONS

Endoscopic treatment may be one of therapeutic options for eligible foregut NETs. However, the appropriate selection criteria of foregut NETs for endoscopic resection is still controversial and further studies are needed.

Conflicts of Interest

The author has no financial conflicts of interest.

REFERENCES

1. Li QL, Zhang YQ, Chen WF, et al. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol 2012;18:5799-5806.
2. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-712.
3. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: The International Agency for Research on Cancer, Bosman TF, Carneiro F, Hruban RH, ed. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer; 2010, p.13.
4. Hruban RH, Pitman MB, Klimstra DS. American Registry of Pathology: Armed Forces Institute of Pathology (U.S.). Tumors of the Pancreas. Washington DC: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology; 2007, p.422.
5. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
6. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One 2013;8:e62487.
7. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655-2664.
8. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-243.
9. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010;105:2563-2569.
10. Scherübl H. Options for gastroenteropancreatic neuroendocrine tumors. Lancet Oncol 2008;9:203.
11. Hosokawa O, Miyanaga T, Kato M, et al. Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol 2008;43:1112-1115.
12. Scherübl H, Cadiot G, Jensen RT, Rösch T, Stölzel U, Kloppe G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 2010;42:664-671.
13. Scherübl H. Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy 2009;41:162-165.
14. Scherübl H, Jensen RT, Cadiot G, Stölzel U, Kloppe G. Neuroendocrine tumors of the small bowels are on the rise: early management. World J Gastrointest Endosc 2010;2:325-334.
15. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.
16. Gencosmanoglu R, Sen-Oran E, Kurkçaya-Yapıcıer O, Atvlez E, Sav A, Toztan N. Gastric polypoid lesions: analysis of 150 endoscopic polypectomy specimens from 91 patients. World J Gastroenterol 2003;9:2236-2239.
17. Scherübl H, Jensen RT, Cadiot G, Stölzel U, Kloppe G. Management of early gastrointestinal neuroendocrine neoplasms. World J Gastroenterol 2011;17:133-139.
18. Zhang L, Ozao J, Warner R, Divino C. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg 2011;35:1879-1886.
19. Borch K, Ahren B, Ahlman H, Falkmer S, Grünérus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated
treatment in relation to type. Ann Surg 2005;242:64-73.
20. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:
453-463.
21. Granberg D, Wilander E, Stridsberg M, Granerus G, Skogseid B, Oberg
K. Clinical symptoms, hormone profiles, treatment, and prognosis in
patients with gastric carcinoids. Gut 1998;43:223-228.
22. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as
serum marker for neuroendocrine neoplasia: comparison with neuron-
specific enolase and the alpha-subunit of glycoprotein hormones. J Clin
Endocrinol Metab 1997;82:2622-2628.
23. Campana D, Nori F, Pizzilli R, et al. Gastric endocrine tumors type I:
treatment with long-acting somatostatin analogs. Endocr Relat Cancer
2008;15:337-342.
24. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum
HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J
Gastroenterol 2004;39:621-628.
25. Shi W, Johnston CE, Buchanan KD, et al. Localization of neuroendo-
crine tumours with [111In] DTPA-octreotide scintigraphy (Octreo-
scan)- a comparative study with CT and MR imaging. QJM 1998;91:
295-301.
26. Rehm H, Wiedemann B, Betz H. Molecular characterization of syn-
aptoophysin, a major calcium-binding protein of the synaptic vesicle
membrane. EMBO J 1986;5:535-541.
27. Erickson JD, Schaefer MK, Bonner TI, Eiden LE, Weihe E. Distinct
pharmacological properties and distribution in neurons and endocrine
cells of two isoforms of the human vesicular monoamine transporter.
Proc Natl Acad Sci U S A 1996;93:5166-5171.
28. Rindi G, Paoloiti D, Fiocca R, Wiedemann B, Henry JP, Solcia E. Ve-
sicular monoamine transporter 2 as a marker of gastric enterochromaf-
fin-like cell tumors. Virchows Arch 2010;456:217-223.
29. Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tu-
mors. Gastroenterol Res Pract 2012;2012:287825.
30. Rindi G, Berli C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carci-
noids and neuroendocrine carcinomas: pathogenesis, pathology, and
behavior. World J Surg 1996;20:168-172.
31. Ravizza D, Fiori G, Trovato C, et al. Long-term endoscopic and clinical
follow-up of untreated type I gastric neuroendocrine tumours. Dig
Liver Dis 2007;39:537-543.
32. Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a
prospective study on endoscopic management and recurrence rate. Ne-
uroendocrinology 2012;95:207-213.
33. Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis
of 1914 reported cases. Cancer 2005;103:1587-1595.
34. Ramage JK, Ahmed M, Ardill J, et al. Guidelines for the management of
gastroenteropancreatic neuroendocrine (including carcinoid) tumours
(NEtS). Gut 2012;61:6-32.
35. Yamamoto C, Aoyagi K, Suekane H, et al. Carcinoid tumors of the duo-
denum: report of three cases treated by endoscopic resection. Endosco-
py 1997;29:218-221.
36. Nishimori I, Morita M, Sano S, et al. Endosonographic-guided endo-
scopic resection of duodenal carcinoid tumor. Endoscopy 1997;29:214-
217.
37. Yoshikane H, Goto H, Niwa Y, et al. Endoscopic resection of small du-
denal carcinoid tumors with strip biopsy technique. Gastrointest Endosc
1998;47:466-470.
38. Zyromski NJ, Kendrick ML, Nagorney DM, et al. Duodenal carcinoid
tumors: how aggressive should we be? J Gastrointest Surg 2001;5:588-
593.
39. Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection
in the management of gastric carcinoid tumors. Endoscopy 2003;35:
203-206.
40. Hopper AD, Bourke MJ, Hourigan LE, Tran K, Moss A, Swan MP. En-
bloc resection of multiple type I gastric carcinoid tumors by endoscop-
ic multiclip mucosectomy. J Gastroenterol Hepatol 2009;24:1516-
1521.
41. Yokoyama S, Takifuji K, Tani M, et al. Endoscopic resection of duode-
nal bulb neuroendocrine tumor larger than 10 mm in diameter. BMC
Gastroenterol 2011;11:67.
42. Nikou GC, Toubanakis C, Moulakakis KG, et al. Carcinoid tumors of
the duodenum and the ampulla of Vater: current diagnostic and thera-
petic approach in a series of 8 patients. Case series. Int J Surg 2011;9:
248-253.
43. Kolby L, Nilsson O, Ahlman H. Gastroduodenal endocrine tumours.
Scand J Gastroenterol 2004;93:317-323.
44. Burke AP, Sobin LH, Feder Spielberg BH, Shekitka KM, Helwig EB. Carci-
noid tumors of the duodenum. A clinicopathologic study of 99 cases.
Arch Pathol Lab Med 1990;114:700-704.